Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRT1419

Small molecule · Inhibitor of Myeloid cell leukemia 1 (MCL1) (MCL1) · developed by Prelude Therapeutics

Phase 1 Most advanced trial (none active)
PRLD Developer
1 Registered trials

What is PRT1419?

PRT1419 is an inhibitor of the anti-apoptotic protein MCL1, a Bcl-2 family member upregulated in cancer cells. It binds MCL1 and prevents it from inactivating pro-apoptotic proteins, promoting apoptosis of cells overexpressing MCL1. It is studied in hematologic malignancies including acute myeloid leukemia and several B-cell lymphomas and leukemias.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Myeloid cell leukemia 1 (MCL1) (MCL1)
Mechanism
Inhibitor of Myeloid cell leukemia 1 (MCL1) (MCL1)
Pathways
apoptosis
Therapy area
Oncology
Developer
Prelude Therapeutics Incorporated (PRLD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05107856 Phase 1 Acute Myeloid Leukemia Terminated PRLD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid LeukemiaB-cell Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaChronic Myelomonocytic LeukemiaFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaMyelodysplastic SyndromesMyeloproliferative NeoplasmSmall Lymphocytic Lymphoma

More from Prelude Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.

Follow PRLD, the company behind PRT1419

See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRLD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.